SEC filing summary
Identity discrepancy: The request metadata names CYPHERPUNK TECHNOLOGIES INC., but the supplied filing is Leap Therapeutics, Inc.’s Form 10-Q for the quarter ended September 30, 2018, filed November 9, 2018. This summary reflects the supplied filing; verify the issuer before relying on it.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing investigational cancer therapies DKN-01 and TRX518. Neither candidate is FDA-approved, and the company had no product revenue. Financial results cover the three and nine months ended September 30, 2018, compared with the same periods in 2017; balance-sheet comparisons are with December 31, 2017.
Key financial metrics
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $6.5 million | $6.8 million | $14.9 million | $18.1 million |
| General and administrative expense | $2.1 million | $1.8 million | $6.9 million | $7.7 million |
| Total operating expenses | $8.6 million | $8.6 million | $21.8 million | $25.8 million |
| Net loss | $6.6 million | $6.8 million | $24.6 million | $23.1 million |
| Net loss per share, basic | $0.45 | $0.73 | $1.76 | $2.72 |
| Cash used in operating activities | Not provided for quarter | Not provided for quarter | $19.0 million | $15.8 million |
At September 30, 2018, cash and cash equivalents were $23.2 million, current assets were $24.4 million, current liabilities were $6.0 million, and total assets were $27.1 million. Stockholders’ equity was $6.6 million and accumulated deficit was $155.0 million. The filing reports a $14.5 million warrant liability, but no conventional borrowings outstanding at period-end. Current assets exceeded current liabilities by approximately $18.3 million. Operating margins are not meaningful because the company reported no revenue.
Changes versus comparable periods
- Q3 net loss narrowed by $0.2 million year over year, despite nearly unchanged operating expenses. A $1.8 million gain from remeasuring warrant liability helped offset lower Australian R&D incentive income and foreign-exchange losses.
- For the first nine months, net loss increased by $1.5 million despite operating expenses falling $4.0 million. The principal offsetting factors included a $3.7 million warrant fair-value loss and less favorable foreign-exchange results.
- Nine-month operating cash use rose by $3.2 million year over year. Cash declined $2.5 million from year-end 2017 to $23.2 million, after $15.9 million of financing cash inflows and a positive $0.5 million exchange-rate effect.
- The March 2018 public offering generated approximately $14.8 million net proceeds; warrant exercises added $1.2 million in the nine-month period. Common shares outstanding increased from 12.35 million at December 31, 2017 to 14.70 million at September 30, 2018.
Outlook, commentary, and risks
- Management expects operating losses and expenses to continue and anticipates increased R&D spending as it advances DKN-01 and TRX518, subject to funding. The filing provides no specific revenue, earnings, or cash-runway guidance.
- Management concluded that substantial doubt exists about the company’s ability to continue as a going concern for one year after issuance of the financial statements. It plans to seek equity financing, government-program funding, collaborations, licenses, or cost-sharing. Without funding, it may delay, reduce, or eliminate trials and R&D programs.
- Management highlighted clinical progress, including reported DKN-01 combination-study response and disease-control results and early TRX518 combination observations. These are investigational, limited clinical findings, not evidence of approved or established efficacy.
- Notable accounting item: the private-placement warrants are Level 3 liabilities measured using a Monte Carlo model. Fair-value changes materially affected reported losses—$1.8 million gain in Q3 and $3.7 million loss for the nine-month period—and are noncash.
- Key risks include clinical-trial outcomes and timing, regulatory approval, additional financing and dilution, manufacturing costs, and patent challenges. The filing describes opposition proceedings involving two TRX518 patents; an EPO hearing on one was scheduled for December 4, 2018. Noncancelable manufacturing commitments were $416,000.
- A subsequent event: Leap received $800,000 of Australian R&D tax-incentive payments on October 25, 2018. Management reported disclosure controls effective and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer and filing identity: the supplied document is Leap Therapeutics, not the company named in the request metadata.
- Assess financing needs and cash runway in light of the explicit going-concern uncertainty, continuing operating cash burn, and absence of product revenue.
- Review the underlying clinical-trial designs, patient counts, follow-up, and data maturity behind the cited response results.
- Check warrant terms, liability valuation assumptions, potential dilution, and the effect of future fair-value changes on reported earnings.
- Track the outcome of the TRX518 patent oppositions and the timing and eligibility of Australian R&D incentive receivables and payments.